Long-term Efficacy and Safety, Including COVID-19 Infections, Among Ozanimod-Treated Patients With Relapsing Multiple Sclerosis in the DAYBREAK Open-Label Extension Trial

Cree, B. A.; Selmaj, K. W.; Steinman, L.; Comi, G.; Bar-Or, A.; Arnold, D. L.; Hartung, H.; Montalban, X.; Havrdova, E. K.; Sheffield, J. K.; Minton, N.; Cheng, C.; Silva, D.; Kappos, L.; Cohen, J. A.

Cree, B. A.; Selmaj, K. W.; Steinman, L.; Comi, G.; Bar-Or, A.; Arnold, D. L.; Hartung, H.; Montalban, X.; Havrdova, E. K.; Sheffield, J. K.; Minton, N.; Cheng, C.; Silva, D.; Kappos, L.; Cohen, J. A..

Multiple Sclerosis Journal ; 28(1_SUPPL):85-86, 2022.

Article in English | Web of Science | ID: covidwho-1865888

Keywords

Neurosciences & Neurology

Search on Google

XML

Collection: Databases of international organizations Database: Web of Science Type of study: Randomized controlled trials Topics: Long Covid Language: English Journal: Multiple Sclerosis Journal Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

XML